alloantibodies developed, directed against the Kell antigen Kpa. Coombs-reactive autoantibodies were detectable; the DAT became strongly positive. As it became difficult to find compatible red cell packs, lenalidomide was initiated in June 2006 despite two previous thrombo-embolic events, with anemia of 57 g/L hemoglobin (Fig. 1) . The patient received 10 mg of lenalidomide daily for 21 days every 4 weeks, supplemented by low-molecular weight heparin [2] . Complicating the course, clinical and laboratory signs of hemolytic anemia appeared on day 20 of lenalidomid, with marked increase of bilirubin and LDH levels ( Fig. 1) and depletion of haptoglobin. Both DAT and IAT were positive. Thus, warm autoimmune hemolytic anemia (AIHA) was diagnosed and high-dose methylprednisolone and immunoglobulin were administered. Lenalidomide was interrupted, but reinitiated on day 29 due to the urgency of response needed. Fortunately, hemolytic activity tapered off within a week, without relapse thereafter.
As expected, neutrophils and platelets declined gradually in the first weeks of lenaliomide ( Fig. 1) , potentially being indicative of subsequent response [3] . Indeed, on the 30th day after start of lenalidomide, the last transfusion was needed. Later, with hemoglobin levels >140 g/L, lenalidomide was reduced to a maintenance dose of 5 mg every other day. Assessed by the recent MDS criteria [4] , both hematologic and cytogenetic responses were complete (March 2008). The therapy was continued until February 2008, thereafter, lenalidomide was withdrawn due to patient's wish. In October 2008, pancytopenia and need for transfusion reappeared. The aberrant karyotype, stable in four evaluations before start of lenalidomide, changed to a complex pattern with deletions 5q and 20q, monosomy 3, and translocations t(X;12), t(3;22), and t(17;21). Transformation to secondary acute leukemia was diagnosed (Fig. 1) . In March 2009, the patient died from septicemia.
Lenalidomide, a novel immunomodulatory drug, was administered successfully in this del(5q) MDS. However, at beginning of lenalidomide, overt hemolysis occurred, which is uncommon in MDS [5, 6] . Generally, autoantibodies can be detected in 20% to 35% of MDS patients, and DAT is positive in a minority (less than 10%) [7, 8] .
Until now, lenalidomide-associated AIHA was observed in one MDS and lymphoma patient each [9, 10] . Thus, our case is the second report on AIHA in MDS during lenalidomide therapy. Lenalidomide-triggered AIHA does indeed seem to represent a clinically relevant side effect. It may be speculated that lenalidomide contributed to exacerbation into manifest hemolysis by inducing effector mechanisms, which by themselves used the preformed autoantibodies for action. Fig. 1 Time evolution of the main parameters from the diagnosis
